JPRN-UMIN000012302招募中未知
The effects of rapid acting insulin on glucose control in basal-bolus insulin treated type2 diabetes. - The effects of rapid acting insulin on glucose control in basal-bolus insulin treated type2 diabetes.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with hypersensitivity to insulin Aspart and/or Lispro. 2) Patients with surgical operation, trauma or infection. 3) Patients who are pregnant 4) Patients with severe renal or liver failure 5) Patients with pituitary insufficiency or adrenal insufficiency. 6) Patients with diarrhea or vomit 7) Patients with heavy exercise 8) Juged as ineligible by clinical investigators
研究者
相似试验
已完成
不适用
The effect of rapid-acting insulin injected by needle-free jet-injection in the management of hyperglycemia in patients with diabetes10018424diabetesNL-OMON38926niversitair Medisch Centrum Sint Radboud20
已完成
不适用
Pharmacology of rapid-acting insulin injected by needle-free jet-injection in patients with diabetes10018424DiabetesNL-OMON35858niversitair Medisch Centrum Sint Radboud24
已完成
不适用
Influence of adjusting rapid-acting insulin aspart on post-exercise nocturnal hypoglycaemia in recreationally active people with type 1 diabetes on insulin degludecE10Type 1 diabetes mellitusDRKS00013509Abertawe Bro Morgannwg Unviersitz Local Health Board, 1St Floor, Institute of Life Science19
已完成
不适用
Studies of insulin action in patients at increased vascular risk: modulation by anti-hypertensive and endocrine replacement therapyHypertension, type two diabetes, hypopituitarismNutritional, Metabolic, EndocrineHypertensionISRCTN84921696Royal Group Hospitals Trust (UK)45
进行中（未招募）
1 期
Studies of insulin action in patients at increased vascular risk. Modulation by antihypertensive and endocrine replacement therapy. - Studies of insulin action in patients at increased vascular riskProtocol (a): Essential Hypertension Protocol (b): Hypertension in Type 2 Diabetes Protocol (c): PanhypopituitarismMedDRA version: 8.1 Level: LLT Classification code 10022489 Term: Insulin resistanceEUCTR2006-001562-16-GBRoyal Group of Hospitals Trust45